Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

OptimizeRx (OPRX) EBIT Margin: 2009-2024

Historic EBIT Margin for OptimizeRx (OPRX) over the last 16 years, with FY2024 value amounting to 14.88%.

  • OptimizeRx's EBIT Margin rose 480400.0% to 7.86% in Q3 2025 from the same period last year, while for Sep 2025 it was 6.17%, marking a year-over-year increase of 382000.0%. This contributed to the annual value of 14.88% for FY2024, which is 220400.0% up from last year.
  • As of FY2024, OptimizeRx's EBIT Margin stood at 14.88%, which was up 220400.0% from 36.91% recorded in FY2023.
  • OptimizeRx's 5-year EBIT Margin high stood at 0.59% for FY2021, and its period low was 36.91% during FY2023.
  • For the 5-year period, OptimizeRx's EBIT Margin averaged around 15.16%, with its median value being 14.88% (2024).
  • Its EBIT Margin has fluctuated over the past 5 years, first crashed by -202700bps in 2022, then soared by 220400bps in 2024.
  • OptimizeRx's EBIT Margin (Annual) stood at 4.93% in 2020, then skyrocketed by 112bps to 0.59% in 2021, then tumbled by -3441bps to 19.68% in 2022, then crashed by -88bps to 36.91% in 2023, then soared by 60bps to 14.88% in 2024.
  • Its last three reported values are 14.88% in FY2024, 36.91% for FY2023, and 19.68% during FY2022.